Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic review methodology or new human data.
PubMed 40906565 · doi:10.1177/08971900251376795
What was done
This was a narrative review synthesizing current literature regarding the reproductive health considerations of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP agonists, focusing on oral contraception interactions, fertility, pregnancy, and lactation.
What was found
The abstract reports no numerical data. Qualitatively, tirzepatide impairs the absorption of oral contraceptives through delayed gastric emptying, whereas other GLP-1RAs show no clinically significant interactions. Fertility outcomes may improve secondary to medication-induced weight loss and metabolic benefits, while safety data regarding use during pregnancy and lactation remain limited.
Why it matters
As GLP-1 receptor agonists become widely prescribed for obesity and diabetes in people of reproductive age, clinicians need clear guidance regarding contraceptive efficacy, unintended pregnancy risks, and medication management across pregnancy and lactation.
Limits
The abstract provides no quantitative endpoints, effect sizes, search strategy details, or sample sizes. Evidence on safety during pregnancy and lactation is explicitly noted as limited.
Cited by
- context GLP-1 receptor agonist medications interfere with the absorption of hormonal contraception.